Gabapentin Dementia Lawsuit

Gabapentin lawsuits are now being investigated because new research has raised concerns that long-term or repeated gabapentin use is linked to dementia, mild cognitive impairment, memory loss, confusion, and other cognitive problems.

These cases are still developing, and we are in the early rounds of this. There is no nationwide gabapentin dementia MDL, no approved class action settlement, and no guaranteed payout. But the science is advancing, and the legal theories are strengthening as the evidence grows.

Gabapentin is one of the most commonly prescribed medications in the United States. It is sold under the brand name Neurontin and is also available as a generic. Doctors prescribe Neurontin for seizures, shingles-related nerve pain, and a long list of off-label conditions, including back pain, neuropathy, anxiety, migraines, fibromyalgia, sleep problems, and other chronic pain complaints.

The core allegation is that drug companies failed to give doctors and patients adequate warnings about the potential cognitive risks of gabapentin, especially when the drug was prescribed for off-label uses where the benefits were often uncertain.

Do not stop taking gabapentin without speaking to your doctor. Suddenly stopping gabapentin can cause withdrawal symptoms and may increase seizure risk in some patients.

Contact us via our online form or call 800-553-8082 if you believe you may have a viable Gabapentin lawsuit.

What Is Gabapentin?

Gabapentin is an anticonvulsant medication. The brand version, Neurontin, was originally developed by Parke-Davis, later tied to Warner-Lambert and Pfizer. The drug is now widely available in generic form.

The FDA-approved uses for Neurontin are narrower than many patients realize. The current label identifies two main uses: (1) management of postherpetic neuralgia in adults, which is nerve pain after shingles, and (2) adjunctive therapy for partial-onset seizures in adults and pediatric patients with epilepsy. In regular medical practice, however, gabapentin is prescribed for many conditions outside those approved uses.

Off-label prescribing in and of itself is not awful. Doctors prescribe FDA-approved drugs for conditions not listed on the label when they believe the medication may help. But drug companies generally cannot market a drug for unapproved uses, and they must provide adequate warnings about known or reasonably knowable risks.

Gabapentin became popular in part because it was seen as a safer alternative to opioids. It was not originally viewed as highly addictive. It was cheap after generic versions became available. Doctors under pressure to reduce opioid prescribing increasingly turned to gabapentin for chronic pain patients. That shift helped make gabapentin a routine medication in pain clinics, primary care offices, and even postoperative care.

The problem is that popularity can outrun proof and it seems that is what has happened here. That is the concern now driving gabapentin dementia lawsuits.

Why Are Gabapentin Lawsuits Being Investigated?

Gabapentin lawsuits are being investigated because several studies have reported associations between gabapentin use and later cognitive problems. These studies do not prove every patient who took gabapentin and later developed dementia has a lawsuit. They do not prove gabapentin caused every case of memory loss. But they do raise enough concern that lawyers, doctors, and patients are paying attention.

The strongest cases will not be built on a vague complaint that a patient “felt foggy” after taking gabapentin. Cognitive fog, dizziness, and sedation have long been known issues with the drug. The emerging lawsuits are focused on something more serious: diagnosed dementia, mild cognitive impairment, early-onset dementia, or major cognitive decline after repeated or long-term gabapentin use.

The logic of these cases is simple. Gabapentin affects the central nervous system. It has long been associated with sedation, dizziness, gait instability, and confusion. It was heavily used for off-label conditions. Now research suggests a relationship between repeated gabapentin prescriptions and later dementia or cognitive impairment. If manufacturers knew or should have known about those Neurontin risks, the label should have clearly warned doctors and patients.

The defense argument is also predictable. Drug companies will say dementia has many causes. They will argue that observational studies cannot prove causation. They will also argue that many patients took generic gabapentin, for which they are not responsible.

That is the fight in a nutshell. Plaintiffs will argue that the warning was inadequate and the risk was foreseeable. Defendants will argue that the science is not strong enough and that the injuries are caused by other factors.

The 2025 Gabapentin Dementia Study That Changed the Conversation

The study getting the most attention was published in Regional Anesthesia & Pain Medicine in 2025. Researchers examined adults with chronic low back pain using the TriNetX database, which includes de-identified electronic health records from many healthcare organizations. The study compared patients who received gabapentin prescriptions with similar patients who did not.

The results were alarming. After matching patients to control for demographics, comorbidities, and other pain medications, researchers found that patients with six or more gabapentin prescriptions had a higher incidence of dementia and mild cognitive impairment within ten years. The reported risk ratio was 1.29 for dementia and 1.85 for mild cognitive impairment. Among non-elderly adults ages 18 to 64, the reported risk was higher, with more than double the risk of dementia and mild cognitive impairment compared to patients not prescribed gabapentin.

Not surprisingly, the study also suggested a dose frequency relationship. Patients with 12 or more prescriptions had higher rates of dementia and mild cognitive impairment than patients with three to eleven prescriptions.

This study gave plaintiffs’ lawyers a stronger scientific foundation than they had before. It also focuses on chronic low back pain, one of the most common off-label reasons patients receive gabapentin. That is relevant because many potential claimants were not taking gabapentin for seizures or shingles-related nerve pain. They were taking it for chronic pain complaints, where the risk-benefit calculation looks very different.

Other Studies on Gabapentin and Cognitive Decline

The 2025 study is not the only research raising concerns. A 2023 study in Frontiers in Pharmacology examined gabapentin or pregabalin exposure using Taiwan’s National Health Insurance Research Database. That study included more than 200,000 patients and reported a higher risk of dementia among patients exposed to gabapentin or pregabalin compared with matched non-exposed patients. The risk increased with higher cumulative defined daily doses.

That study is useful for plaintiffs because it suggests a dose-response relationship. In drug litigation, dose-response evidence is useful to victims’ lawyers. If higher exposure is associated with higher risk, plaintiffs’ attorneys can argue that the relationship is less likely to be random.

Another study, published in Frontiers in Pharmacology in 2022, looked at older adults with normal cognition using data from the National Alzheimer’s Coordinating Center. Researchers found that gabapentin initiation was associated with certain neurocognitive and functional declines, including changes in Clinical Dementia Rating scores and functional measures. The study also found increased falls in a subgroup.

Why Off-Label Use Matters

Off-label use will be a major issue in these lawsuits. Gabapentin was approved for seizures and postherpetic neuralgia. But many patients received it for chronic back pain, general neuropathy, anxiety, insomnia, migraines, fibromyalgia, and other conditions.

That matters because a patient taking gabapentin for epilepsy may face a very different risk-benefit calculation than a patient taking it for routine low back pain. Seizures can be life-threatening. Postherpetic neuralgia can be severe. But chronic back pain is often treated with multiple therapies, and if gabapentin provides limited benefit for some patients while carrying potential cognitive risks, the warning and prescribing decision becomes more important.

Pfizer’s history with off-label Neurontin marketing will also get attention. In 2004, Warner-Lambert agreed to pay $430 million to resolve criminal and civil allegations tied to illegal promotion of Neurontin for unapproved uses. Federal prosecutors described a national off-label marketing campaign that included promotion for conditions not approved by the FDA.

That old settlement did not compensate dementia victims. It did not resolve today’s potential cognitive impairment claims. But it shows that Neurontin’s off-label marketing history is not speculation. So we will argue that the same off-label expansion that made gabapentin so widely used also exposed patients to risks they were not adequately warned about.

What Does the Gabapentin Label Warn About?

The current Neurontin label warns about several serious risks, including drug reaction with eosinophilia and systemic symptoms, anaphylaxis and angioedema, effects on driving and operating heavy machinery, somnolence, dizziness, suicidal behavior and ideation, withdrawal-related seizure risk, respiratory depression, pediatric neuropsychiatric adverse reactions, and other concerns.

The label does not contain a clear warning that gabapentin may increase the risk of dementia or mild cognitive impairment. Plaintiffs will argue that a central nervous system drug used repeatedly over months or years should have carried stronger cognitive warnings as evidence developed.

Who May Qualify for a Gabapentin Dementia Lawsuit?

Every case is different, but the strongest potential Neurontin lawsuit will usually involve a patient who took gabapentin repeatedly or long term and later developed a serious cognitive diagnosis. A casual user who took a short course of gabapentin and later had vague memory complaints will be much harder to pursue.

You may have a stronger case if several of these facts apply:

• You took gabapentin or Neurontin for months or years.
• You received multiple prescriptions, especially six or more prescriptions.
• You were prescribed gabapentin for an off-label condition such as chronic back pain, migraines, anxiety, fibromyalgia, or general chronic pain.
• You were later diagnosed with dementia, mild cognitive impairment, early-onset dementia, or significant documented cognitive decline.
• You were under age 65 when the cognitive diagnosis was made.
• You did not have major pre-existing dementia risk factors that clearly explain the diagnosis.
• Your medical records show a timeline connecting gabapentin use and later cognitive decline.
• You or your family noticed confusion, memory problems, functional decline, or personality changes after repeated gabapentin use.

The under-65 issue matters because early-onset dementia claims may be easier to separate from ordinary age-related cognitive decline. That does not mean older patients have no case. Many older adults may still have valid claims. But defendants will argue that dementia in older patients is common and often caused by other medical factors. The younger the patient, the more attention the medication history may receive.

Who May Have a Weaker Claim?

Not every gabapentin user with memory problems has a viable lawsuit. A weak case may involve short-term use, unclear diagnosis, no medical documentation, or a long list of alternative causes that make causation difficult.

Cases may be harder where the patient had a prior dementia diagnosis before taking gabapentin, a history of stroke, traumatic brain injury, advanced Alzheimer’s disease before exposure, heavy alcohol use, severe uncontrolled diabetes, major vascular disease, or other strong independent explanations for cognitive decline.

Cases may also be more difficult when the only product used was generic gabapentin. Generic drug lawsuits face complicated federal preemption defenses because generic manufacturers are generally required to match the brand-name label. Some states allow claims against the brand-name manufacturer even when the patient took a generic version under an innovator liability theory (a doctrine explicitly recognized in states like California), but many do not. That is a major legal issue and will depend heavily on state law.

What Compensation Could Be Available?

There is no current average gabapentin lawsuit settlement amount. Any website giving a confident average payout for gabapentin dementia lawsuits is guessing. These cases are too new. There is no dementia MDL settlement grid, no bellwether verdict, and no established global settlement.

If these Neurontin cases move forward, potential damages could include medical expenses, future dementia care, assisted living costs, in-home care, lost wages, loss of earning capacity, pain and suffering, emotional distress, loss of independence, and the impact on family members. In wrongful death cases, damages may include funeral expenses, loss of companionship, and other damages allowed by state law.

The biggest value driver will be the severity of the cognitive injury. A mild memory complaint with limited treatment is not the same as early-onset dementia that forces a person out of work and into assisted care. The second biggest driver will be causation. You need to establish that the drug caused the injury. A devastating injury still requires proof that gabapentin was a substantial factor in causing or contributing to the harm.

Prior Neurontin Settlements and Verdicts

Gabapentin already has a significant litigation history, but prior Neurontin settlements were mostly about off-label marketing, insurance payments, and antitrust issues. They were not dementia settlements for injured patients.

The legal takeaway is not that Pfizer has already settled dementia claims. It has not. The takeaway is that Neurontin has a documented history of aggressive off-label marketing and major litigation. Victims’ lawyers in new dementia lawsuits will try to connect that history to today’s argument that gabapentin was overprescribed for conditions where patients were not warned about long-term cognitive risk.

Is There a Gabapentin Class Action Lawsuit?

There is no nationwide gabapentin dementia class action settlement right now. These cases, if filed, are more likely to proceed as individual product liability lawsuits rather than a traditional class action.

That makes sense. Dementia injuries are highly individual. One person may have mild cognitive impairment and continue working. Another may develop early-onset dementia and need full-time care. One patient may have taken gabapentin for back pain for years. Another may have taken it briefly after shingles. One patient may have taken brand-name Neurontin. Another may have taken only generics. Those differences matter.

Mass torts are often coordinated through an MDL if many lawsuits are filed around the country. An MDL is not the same as a class action. In an MDL, each plaintiff keeps an individual case, but the cases are coordinated before one judge for discovery and pretrial rulings. If gabapentin dementia lawsuits grow, plaintiffs may eventually seek consolidation. But as of June 2026, no national gabapentin dementia MDL appears to have been created.

Gabapentin Lawsuit Updates

June 2026: Gabapentin Dementia Claims Are Being Investigated

Law firms are now reviewing potential gabapentin dementia and cognitive impairment claims. The focus is on patients who took gabapentin repeatedly, often for off-label pain conditions, and later developed dementia, mild cognitive impairment, or serious memory loss.

There is still no approved settlement and no court-established compensation program. These Neurontin claims are in the investigation stage. That means lawyers are collecting records, reviewing medical literature, analyzing state law, and determining which cases may be strong enough to file.

2025: New Chronic Back Pain Study Raises Concern

The 2025 chronic low back pain study has become one of the strongest pieces of evidence for potential claims. It reported increased dementia and mild cognitive impairment diagnoses among patients with repeated gabapentin prescriptions, with higher risks in non-elderly adults and in patients with more prescriptions.

This study does not prove causation by itself. But it gives plaintiffs a concrete scientific basis for asking whether doctors and patients should have been warned more clearly about Neurontin’s cognitive risks.

2024: Study Shows Mixed Evidence in Older Adults With Cognitive Impairment

A 2024 study in older adults with existing cognitive impairment did not find a significant association between gabapentin initiation and cognitive or functional decline over one to two years, but it did report increased falls. This study will likely be used by the defense to argue that the science is mixed.

That does not end the litigation. It means plaintiffs will need strong experts who can explain why some studies are more relevant to certain patients than others, especially younger patients, chronic pain patients, and patients with repeated prescriptions.

2023: Taiwan Database Study Reports Higher Dementia Risk

The 2023 Taiwan database study found an increased dementia risk among patients exposed to gabapentin or pregabalin and reported higher risks with increasing cumulative exposure. Plaintiffs will likely rely on this study as part of the broader body of evidence.

Defendants will argue that gabapentin and pregabalin were grouped together and that foreign insurance database findings do not prove causation in individual U.S. cases. Both sides will have arguments. That is why expert testimony will drive these cases.

2019: FDA Adds Breathing Risk Warning

The FDA required new gabapentinoid warnings for serious breathing problems in 2019, especially in patients using opioids or other central nervous system depressants, patients with respiratory disease, and older adults. This warning is not about dementia, but it shows that gabapentin safety concerns have continued to evolve long after the drug became widely used.

Gabapentin Lawsuit FAQs

Getting Help from a Lawyer with Your Compensation Claim

If you or a loved one took gabapentin and later developed dementia, mild cognitive impairment, or severe memory loss, the next step is to call a lawyer. You can reach us at 800-553-8082 or get a free online consultation.